7 facts on metoclopramide utility Review article
Article Sidebar
Published:
Dec 31, 2020
Keywords:
metoclopramide, nausea, vomiting, migrane, gastroparesis, extra-pyramidal syndrome
Main Article Content
Abstract
Nausea and vomiting can be either a symptom, or an adverse reaction to treatment. Metoclopramide is an effective agent that can be used to treat nausea and vomiting due to inhibition effect on dopamine D2 receptor and histamine 5-HT3 receptor, causing accelerated gastric emptying, as well as increased gut motility. It is effective in treatment of nausea and vomiting regardless of cause. Some conditions with evidence (based on randomized clinical trials) of metoclopramide effectiveness include migraine, diabetic gastroparesis, patients after chemo- or radiotherapy, after surgery. Even though there is a risk of serious adverse events (including extra-pyramidal syndrome), metoclopramide can be regarded as safe, assuming appropriate patient selection. It can be used also during pregnancy, as well as in pediatric setting, where long-lasting adverse outcomes are observed extremely rarely.
Article Details
How to Cite
Bugajski , M. (2020). 7 facts on metoclopramide utility. Medycyna Faktow (J EBM), 13(4(49), 498-502. https://doi.org/10.24292/01.MF.0420.18
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Davis CJ, Harding RK, Leslie RA et al. The organisation of vomiting as a protective reflex: a commentary on the first day’s discussions. In: Nausea and Vomiting: Mechanisms and Treatment. Springer-Verlag, Berlin 1986: 65-75.
2. Sanger GJ, Andrews PLR. A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research. Front Pharmacol. 2018; 9: 913.
3. Rosenfeld MR, Dvorkin B, Klein PN et al. Differential affinities of molindone, metoclopramide and domperidone for classes of [3H] spiroperidol binding sites in rat striatum: evidence for pharmacologically distinct classes of receptors. Brain Res. 1982; 235: 205-11.
4. Metoklopramid (access: 25.11.2020).
5. Grover M, Farrugia G, Stanghellini V. Gastroparesis: a turning point in understanding and treatment. Gut. 2019; 68: 2238-50.
6. Camilleri M, Parkman HP, Shafi MA et al. American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013; 108: 18-37.
7. Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev Endocrinol Metab. 2010; 5(5): 653-62.
8. Lipton RB, Stewart WF, Diamond S et al. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001; 41: 646-57.
9. Colman I, Brown MD, Innes GD et al. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ. 2004; 329: 1369-73.
10. Diener H-C, Holle-Lee D, Nägel S et al. Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clinical and Translational Neuroscience. 2019. http://doi.org/10.1177/2514183X18823377.
11. Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013; 4: CD008040.
12. Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013; 4: CD008041.
13. De Mulder PH, Seynaeve C, Vermorken JB et al. Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting: A Multicenter, Randomized, Double-Blind, Crossover Study. Ann Intern Med. 1990; 113(11): 834-40.
14. De Oliveira GS Jr, Castro-Alves LJ, Chang R et al. Systemic metoclopramide to prevent postoperative nausea and vomiting: a meta-analysis without Fujii’s studies. Br J Anaesth. 2012; 109(5): 688-97.
15. Henzi I, Walder B, Tramer MR. Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies. Br J Anaesth. 1999; 83: 761-71.
16. Bolton CM, Myles PS, Nolan T et al. Prophylaxis of postoperative vomiting in children undergoing tonsillectomy: a systematic review and meta-analysis. Br J Anaesth. 2006; 97(5): 593-604.
17. Lau Moon Lin M, Robinson PD, Flank J et al. The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis. Drug Saf. 2016; 39(7): 675-87.
18. Fedorowicz Z, Jagannath VA, Carter B. Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. Cochrane Database Syst Rev. 2011; 9: CD005506.
19. Koren G. Safety considerations surrounding use of treatment options for nausea and vomiting in pregnancy. Expert Opin Drug Saf. 2017; 16(11): 1227-34.
20. Mishriky BM, Habib AS. Metoclopramide for nausea and vomiting prophylaxis during and after Caesarean delivery: a systematic review and meta-analysis. Br J Anaesth. 2012; 108(3): 374-83.
21. Ganzini L, Casey DE, Hoffman WF et al. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med. 1993; 153(12): 1469-75.
22. Avorn J, Gurwitz JH, Bohn RL et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA. 1995; 274(22): 1780-2.
23. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010; 31(1): 11-9.
24. Parlak I, Atilla R, Cicek M et al. Rate of metoclopramide infusion affects the severity and incidence of akathisia. Emerg Med J. 2005; 22: 621-4.
2. Sanger GJ, Andrews PLR. A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research. Front Pharmacol. 2018; 9: 913.
3. Rosenfeld MR, Dvorkin B, Klein PN et al. Differential affinities of molindone, metoclopramide and domperidone for classes of [3H] spiroperidol binding sites in rat striatum: evidence for pharmacologically distinct classes of receptors. Brain Res. 1982; 235: 205-11.
4. Metoklopramid (access: 25.11.2020).
5. Grover M, Farrugia G, Stanghellini V. Gastroparesis: a turning point in understanding and treatment. Gut. 2019; 68: 2238-50.
6. Camilleri M, Parkman HP, Shafi MA et al. American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013; 108: 18-37.
7. Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev Endocrinol Metab. 2010; 5(5): 653-62.
8. Lipton RB, Stewart WF, Diamond S et al. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001; 41: 646-57.
9. Colman I, Brown MD, Innes GD et al. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ. 2004; 329: 1369-73.
10. Diener H-C, Holle-Lee D, Nägel S et al. Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clinical and Translational Neuroscience. 2019. http://doi.org/10.1177/2514183X18823377.
11. Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013; 4: CD008040.
12. Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013; 4: CD008041.
13. De Mulder PH, Seynaeve C, Vermorken JB et al. Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting: A Multicenter, Randomized, Double-Blind, Crossover Study. Ann Intern Med. 1990; 113(11): 834-40.
14. De Oliveira GS Jr, Castro-Alves LJ, Chang R et al. Systemic metoclopramide to prevent postoperative nausea and vomiting: a meta-analysis without Fujii’s studies. Br J Anaesth. 2012; 109(5): 688-97.
15. Henzi I, Walder B, Tramer MR. Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies. Br J Anaesth. 1999; 83: 761-71.
16. Bolton CM, Myles PS, Nolan T et al. Prophylaxis of postoperative vomiting in children undergoing tonsillectomy: a systematic review and meta-analysis. Br J Anaesth. 2006; 97(5): 593-604.
17. Lau Moon Lin M, Robinson PD, Flank J et al. The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis. Drug Saf. 2016; 39(7): 675-87.
18. Fedorowicz Z, Jagannath VA, Carter B. Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. Cochrane Database Syst Rev. 2011; 9: CD005506.
19. Koren G. Safety considerations surrounding use of treatment options for nausea and vomiting in pregnancy. Expert Opin Drug Saf. 2017; 16(11): 1227-34.
20. Mishriky BM, Habib AS. Metoclopramide for nausea and vomiting prophylaxis during and after Caesarean delivery: a systematic review and meta-analysis. Br J Anaesth. 2012; 108(3): 374-83.
21. Ganzini L, Casey DE, Hoffman WF et al. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med. 1993; 153(12): 1469-75.
22. Avorn J, Gurwitz JH, Bohn RL et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA. 1995; 274(22): 1780-2.
23. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010; 31(1): 11-9.
24. Parlak I, Atilla R, Cicek M et al. Rate of metoclopramide infusion affects the severity and incidence of akathisia. Emerg Med J. 2005; 22: 621-4.